Related Experiment Video
Updated: Jul 4, 2026
09:11
Genome Editing with CompoZr Custom Zinc Finger Nucleases (ZFNs)
Published on: June 14, 2012
Zinc-finger nucleases: the next generation emerges
1Institute of Virology (CBF), Charité Medical School, Berlin, Germany. toni.cathomen@charite.de
Summary
Zinc-finger nucleases (ZFNs) enhance gene targeting efficiency by creating DNA double-strand breaks, significantly advancing gene therapy potential. This breakthrough enables precise human genome modification for therapeutic applications.
Area of Science:
- Genetics and Genomics
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy holds promise for revolutionizing medicine through precise human genome modification.
- Homologous recombination (HR) based gene targeting has been limited by low efficiency in mammalian cells.
- Previous reliance on selection methods hindered therapeutic application of gene targeting.
Purpose of the Study:
- To review recent advances in zinc-finger nucleases (ZFNs) for gene targeting.
- To discuss the potential of ZFNs in overcoming previous limitations of HR-based gene therapy.
- To explore upcoming challenges and future experimental work for clinical translation of ZFN technology.
Main Methods:
- Utilizing customized zinc-finger nucleases (ZFNs) to create targeted DNA double-strand breaks (DSBs) in the human genome.
- Leveraging cellular DNA repair pathways, specifically homologous recombination (HR), to facilitate gene targeting.
- Assessing gene conversion frequencies in the absence of external selection markers.
Main Results:
- ZFNs significantly enhance gene targeting efficiency by several orders of magnitude.
- Achieved gene conversion frequencies of up to 29% without the need for selection.
- Demonstrated the potential of ZFN-induced DSBs to stimulate HR-based gene modification.
Conclusions:
- ZFN technology represents a major advancement for HR-based gene therapy strategies.
- The high efficiency of ZFNs in promoting gene targeting paves the way for clinical applications.
- Further research is required to address safety and experimental challenges for clinical translation.
Related Concept Videos
03:00Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...